|
0
|
|
Pharmacogenomic Variability in Adolescents and Youth with Virologic Rebound While Receiving Injectable Cabotegravir/Rilpivirine: A Multi-case Series.
(linkinghub.elsevier.com)
|
Howze TJ
…
Patel ND
International Journal of Antimicrobial Agents
2026-07-29
|
#hiv
#pharmacogenomics
#drug metabolism
#amr
|
|
0
|
|
Nef and Vpu protect infected cells from ADCP mediated by plasma from people with HIV-1.
(journals.asm.org)
|
Belanger E
…
Finzi A
mBio
2026-07-29
|
#hiv
#immunity
#antibody
#phagocytosis
#virulence
|
|
0
|
|
Antiviral Effect, Safety, and Tolerability of Oral VH4011499 (VH-499), a New HIV-1 Capsid Inhibitor: Proof-of-Concept Trial.
(academic.oup.com)
|
Griesel R
…
Benn P
Clinical Infectious Diseases
2026-07-29
|
#hiv
#pharmacokinetics
#inhibitor
#amr
|
|
0
|
|
Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.
(nejm.org)
|
Rockstroh JK
…
Orkin C
New England Journal of Medicine
2026-07-29
|
#hiv
#clinical trial
#pharmacotherapy
#adherence
|
|
0
|
|
MITD1 restricts HIV-1 release by targeting ESCRT-III proteins.
(linkinghub.elsevier.com)
|
Zoladek J
…
Nisole S
Cell Reports
2026-07-29
|
#hiv
#immunity
#viral egress
#interferon
#restriction-factors
|